Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing a pipeline of innovative cancer therapies. The company's pipeline includes SNDX-5613, a highly selective Menin-MLL binding interaction inhibitor for the treatment of MLLr and NPM1 acute leukemia patients. Syndax is also developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, for chronic graft-versus-host disease, and entinostat, a Class I HDAC inhibitor.